Olema Pharmaceuticals
- Market cap
- 694.73M
- P/E (TTM)i
- -3.75
- P/Bi
- 1.61
- EPSi
- -1.87
- Div yieldi
- 0.00%
- 52W posi
- 4%
Anonymous reader poll. Unscientific, not investment advice.
About Olema Pharmaceuticals
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
- Founded
- 2006
- CEO
- Dr. Sean P. Bohen, M.D.,PhD
- Employees
- 131
- Headquarters
- San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- olema.com
Company profile
- Exchange
- US
- Symbol
- OLMA
- Market-cap rank
- #3521
- Listing date
- 2020-11-19
- Market cap
- 694.73M
- Float cap
- 470.37M
- Shares out
- 87.50M
- Float shares
- 59.24M
Sectors & themes
Quote time 2026-10-08 07:38:44 · For reference only, not investment advice and not tailored to your situation.